LD-2 disclosure · Registration
DENDREON CORP.
Coverage · Registration filing — establishes the registrant/client relationship. No periodic income or expenses are reported at registration.
Client
- Name
- DENDREON CORP.
- Description
- Biotechnology manufacturer.
- Location
- Washington · United States of America
Registrant
- Description
- Government affairs and public policy consulting firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesMedicare/Medicaid
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Policy issues relating to corproate tax reform.
LobbyistsCHRIS JONES · ADAM HIGGINS
Covered position (CHRIS JONES): Chief of Staff/Rep. Mike FergusonDeputy Chief of Staff/Rep. David McIntoshCommunications Dir./House Govt. Reform and Oversight SubcmtePress Secretary/Rep. John Myers
Taxation/Internal Revenue Code
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Policy issues relating to corproate tax reform.
LobbyistsCHRIS JONES · ADAM HIGGINS
Covered position (CHRIS JONES): Chief of Staff/Rep. Mike FergusonDeputy Chief of Staff/Rep. David McIntoshCommunications Dir./House Govt. Reform and Oversight SubcmtePress Secretary/Rep. John Myers
Health Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Policy issues relating to corproate tax reform.